Symrise has signed a minority investment agreement with Bonumose, a sugar alternatives specialist and inventor of enzyme solutions.
US-based Bonumose is an early-stage ingredient manufacturer. It produces monosaccharides – alternatives to sucrose – such as tagatose and allulose.
Symrise said that the transaction will accelerate growth in its sugar reduction initiatives, which represents a high-priority focus for the North America region within its Taste, Nutrition and Health segment.
Founded in 2016 as a start-up, Bonumose opened a new R&D facility and manufacturing plant earlier this year. Its patented enzymatic technology enables sustainable bulk production of healthy ingredients from globally-abundant plant material.
Nick Russell, senior VP, Business Incubation Group at Symrise said the investment forms a strategic partnership that will enhance Symrise’s flavour and taste balancing technologies, particularly within the beverage and ice cream categories.
“Combining our technologies will enable us to offer our customers new pathways to sugar reduction and taste balancing solutions. In turn, this will allow them to reduce sugar while optimising the taste of better-for-you products for their consumers,” Russell said.
“Health forms a growing focus category for Symrise. With the support of Bonumose’s enzymatic expertise, we can bring novel and disrupting ingredients to the marketplace together.”
Headquartered in Germany, Symrise is a global supplier of fragrances, flavours, cosmetic active ingredients, functional ingredients and raw materials.
© FoodBev Media Ltd 2023